Weiss-Aug Consolidates Divisions into Two Industry-Focused Business Units

Weiss-Aug, East Hanover, NJ, has completed a strategic rebranding initiative aimed at streamlining its organizational structure and unifying its market presence. The company will transition from operating as Weiss-Aug Group and multiple divisions—previously named after acquired entities—into two newly defined business units: Weiss-Aug and Weiss-Aug MedPharma, each dedicated to serving distinct industry segments.

Weiss-Aug will serve the industrial and commercial sectors, specializing in high-volume metal stamping, thermoplastic molding, and value-added assembly for the aerospace and defense, automotive, interconnect, telecommunications and consumer-goods industries.

Weiss-Aug MedPharma will serve the medical and pharmaceutical industries, primarily focused on medical devices, orthopedic solutions and drug-delivery technologies. Specializing in precision machining, laser processing and insert molding, the business unit will be dedicated to the development and manufacturing of high-quality, precision medical components, assemblies and finished devices.

Lupine Research will remain the firm’s R&D center, focused on artificial intelligence, machine learning and materials science.

“Our new structure represents a significant step forward in aligning our brand with the value we bring to our customers,” says Elisabeth Weissenrieder-Bennis, president of Weiss-Aug. “By retiring legacy names from past acquisitions and uniting our capabilities under these focused business units, we are better positioned to deliver industry-specific expertise, drive innovation, and scale with our customers’ needs.”

The reorganization follows several years of strategic investments in infrastructure, technology and talent, including the development of two new, state-of-the-art facilities in NJ and PA with more than 144,000 sq. ft. of manufacturing space.

See also: Weiss-Aug Group

Technologies: Management

Subscribe to the Newsletter

Start receiving newsletters.